PADI4 and COVID-19: Furthermore, one of the intracellular mechanisms driving NETosis involves the activation of peptidylarginine deiminase-4 (PAD4), as evidenced by reduced NETs release from blood neutrophils of COVID-19 patients following Cl-amidine treatment (a PAD4 inhibitor).